Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant-palonosetron FDC vs granisetron + aprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting
KCT0001495Phase 3Recruiting
- Sponsor
- Helsinn
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of netupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Helsinn. Started Jan 2015; status: recruiting.
02
Drugs
netupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on KCT0001495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001495.